Department of Radiation Oncology & Proton Medical Research Center, University of Tsukuba, Tsukuba, Ibaraki, Japan
Radiation Oncology Department, The Japanese Foundation for Cancer Research, Tokyo, Japan.
Int J Gynecol Cancer. 2020 Apr;30(4):473-479. doi: 10.1136/ijgc-2019-000925. Epub 2020 Mar 11.
Various brachytherapy options are available for treating cervical cancer. This study investigated whether pre-brachytherapy magnetic resonance imaging (MRI) findings could help identify the appropriate brachytherapy technique for cervical cancer.
We retrospectively evaluated patients with cervical cancer who underwent pre-brachytherapy MRI within 7 days before their first high-dose rate brachytherapy treatment between December 2009 and September 2015. Patients who could not undergo MRI at pre-treatment and/or pre-brachytherapy and complete radical radiotherapy were excluded. Conventional intracavitary brachytherapy was the preferred treatment for ≤4 cm and symmetrical tumors. Non-conventional intracavitary brachytherapy, including interstitial brachytherapy, was the preferred treatment for bulky tumors, asymmetrical tumors, tumors with severe vaginal invasion, or bulky barrel-shaped tumors. The 3-year rates of overall survival, disease-free survival, and local control were compared using the Kaplan-Meier method and the log-rank test. Overall survival and local control rates were assessed using Cox regression analysis to identify risk factors for poor overall survival and local control outcomes.
A total of 146 patients were included in the study. The median tumor sizes were 52 mm (range 17-85) at the pre-treatment MRI and 30 mm (range 0-78) at the pre-brachytherapy MRI. Six patients had International Federation of Gynecology and Obstetrics (FIGO) stage IB2, 67 patients had stage II, 64 patients had stage III, and nine patients had stage IVA disease. A total of 124 (85%) patients had squamous cell carcinoma and 22 (15%) patients had adenosquamous cell carcinoma or adenocarcinoma. The MRI findings showed severe vaginal invasion (pre-treatment: 19 patients, pre-brachytherapy: 10 patients), asymmetrical bulky tumors (pre-treatment: 28 patients, pre-brachytherapy: 16 patients), and severe corpus invasion (pre-treatment: 39 patients, pre-brachytherapy: 18 patients). Based on the pre-brachytherapy MRI findings, non-conventional intracavitary brachytherapy was administered to 34 (23.3%) patients. Brachytherapy seemed to be appropriate for 133 (91.1%) patients and inappropriate for 13 (8.9%) patients. The 3-year rates were 84.2% for overall survival and 90.1% for local control. Grade 3 late rectal complications occurred in two (1%) patients. Multivariate analysis showed that tumor characteristics (size, shape, and extent of invasion) were not risk factors, although inappropriate brachytherapy was significantly related to poor local control (p<0.001).
Pre-brachytherapy MRI may help to select appropriate brachytherapy for cervical cancer and reduce the likelihood of inappropriate brachytherapy leading to poor local control.
治疗宫颈癌有多种近距离放疗选择。本研究旨在探讨宫颈癌患者在首次高剂量率近距离放疗前 7 天内行近距离放疗前磁共振成像(MRI)检查的结果能否有助于选择合适的近距离放疗技术。
我们回顾性分析了 2009 年 12 月至 2015 年 9 月期间因首次高剂量率近距离放疗而行近距离放疗前 MRI 检查且可接受 MRI 检查和根治性放疗的宫颈癌患者。排除了无法在治疗前和(或)近距离放疗前进行 MRI 检查且无法完成根治性放疗的患者。常规腔内近距离放疗适用于肿瘤直径≤4cm 和肿瘤对称的患者。非常规腔内近距离放疗,包括间质近距离放疗,适用于肿瘤体积大、不对称、阴道侵犯严重或体积大的桶状肿瘤。采用 Kaplan-Meier 法和对数秩检验比较总生存率、无疾病生存率和局部控制率。采用 Cox 回归分析评估总生存率和局部控制率,以确定总生存率和局部控制率不良的危险因素。
本研究共纳入 146 例患者。预处理 MRI 时肿瘤的中位大小为 52mm(范围 17-85mm),近距离放疗前 MRI 时肿瘤的中位大小为 30mm(范围 0-78mm)。6 例患者为国际妇产科联合会(FIGO)分期 IB2 期,67 例为 II 期,64 例为 III 期,9 例为 IVA 期。124 例(85%)患者为鳞癌,22 例(15%)患者为腺鳞癌或腺癌。MRI 检查结果显示严重阴道侵犯(预处理:19 例,近距离放疗前:10 例)、不对称大肿瘤(预处理:28 例,近距离放疗前:16 例)和严重子宫体侵犯(预处理:39 例,近距离放疗前:18 例)。根据近距离放疗前 MRI 检查结果,34 例(23.3%)患者接受了非传统腔内近距离放疗。133 例(91.1%)患者的近距离放疗似乎合适,13 例(8.9%)患者的近距离放疗不合适。3 年总生存率为 84.2%,局部控制率为 90.1%。两名(1%)患者发生 3 级晚期直肠并发症。多因素分析显示,肿瘤特征(大小、形状和侵犯程度)不是危险因素,尽管不适当的近距离放疗与较差的局部控制显著相关(p<0.001)。
近距离放疗前 MRI 可能有助于选择宫颈癌合适的近距离放疗技术,并降低不适当的近距离放疗导致局部控制不良的可能性。